Skip to main content
. 2022 Mar 15;23(6):3155. doi: 10.3390/ijms23063155

Table 1.

Select antigen-specific Treg studies in human type 1 diabetes.

Method Autoantigen Target(s)
[HLA(s)]
Primary Outcome References
Tetramer staining IGRP [DR3, DR4] IL-10 [39]
Cytokine ELISPOT Insulin B:9–23; mimotopes [DQ8] IL-10 [40]
HIPs [DQ8] IL-10 [42,43]
Proinsulin, IA-2 [DR4] IL-10 [41]
Cloning, cytokine ELISA; flow cytometry Proinsulin, IA-2 IL-10;
[DR3, DR4] granzyme A, B; [48]
Treg suppression
Cytokine beads; flow cytometry GAD65, PPI, IGRP IL-10; IP-10 [49]
Cloning; cytokine ELISA; flow cytometry;
TCR-peptide-MHC crystallization
Proinsulin [DR4] IL-10, granzyme B; TCR-peptide-MHCdocking [51]
Tetramer staining, cloning, flow cytometry GAD, IGRP, PPI, ZnT8
[DR3, DR4, DR15, DQ6]
IL-10; Treg suppression [53]

Treg: regulatory T cell; HLA: human leukocyte antigen; ELISpot: enzyme-linked immune absorbent spot; ELISA: enzyme-linked immunosorbent assay; IGRP: islet-specific glucose-6-phosphatase catalytic subunit-related protein; HIP: hybrid insulin peptide; IA-2: islet antigen-2; GAD65: glutamic acid decarboxylase 65-kilodalton isoform, PPI: preproinsulin; ZnT8: zinc transporter 8; IL: interleukin; TCR: T cell receptor; MHC: major histocompatibility complex.